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Supplemental information 
Supplemental Table 1. Crystallographic data collection and refinement statistics. Related 
to Figure 1. 
RAVV GP-MR191 
Wavelength (Å) 1.033 
Resolution range (Å) 46.17-3.17 (3.29-3.17) 
Space Group P 3 2 1 
Unit Cell (a,b,c in Å; α,β,γ in °) a = 133.8, b = 133.8, c = 150.9 
α = 90,	  β	  =	  90,	  γ	  =120 
Total reflections 296,807 (30,602) 
Unique reflections 26,795 (2,652) 
Multiplicity 11.0 (11.5) 
Completeness (%) 99.28 (98.38) 
Mean I/σ(I) 12.4 (1.3) 
Wilson B-factor 98.1 
R-merge 0.16 (2.02) 
R-measured 0.17 
CC(1/2) 0.998 (0.683) 
CC* 1 (0.901) 
Reflections used for R-free 1,360 
R-work 0.263 (0.423) 
R-free 0.291 (0.405) 
Number of non-hydrogen atoms 5,687 
Macromolecule atoms 5,559 
Glycan atoms 128 
Water 0 
Protein residues 729 
RMS (bonds) 0.012 
RMS (angles) 1.52 
Ramachandran favored (%) 95.0 
Ramachandran allowed (%) 5.0 
Ramachandran outliers (%) 0.0 
Clashscore 6.1 


















Residue! Sequence! Kabat! IMGT!
CDR:H1!
G! 26! 26! 27!
V! 27! 27! 28!
S! 28! 28! 29!
I! 29! 29! 30!
S! 30! 30! 33!
D! 31! 31! 34!
N! 32! 32! 35!
S! 33! 33! 36!
Y! 34! 34! 37!
Y! 35! 35! 38!
CDR:H2!
T! 52! 50! 55!
I! 53! 51! 56!
S! 54! 52! 57!
Y! 55! 53! 58!
S! 56! 54! 59!
G! 57! 55! 60!
N! 58! 56! 64!
T! 59! 57! 65!
Y! 60! 58! 66!
Y! 61! 59! 67!
N! 62! 60! 68!
P! 63! 61! 69!
S! 64! 62! 70!
L! 65! 63! 71!
K! 66! 64! 72!
S! 67! 65! 74!
CDR:H3!
Q! 100! 95! 107!
R! 101! 96! 108!
I! 102! 97! 109!
V! 103! 98! 110!
S! 104! 99! 111!
G! 105! 100! 111A!
F! 106! 100A! 111B!
V! 107! 100B! 111C!
E! 108! 100C! 112B!
W! 109! 100D! 112A!
L! 110! 100E! 112!
S! 111! 100F! 113!
K! 112! 100G! 114!
F! 113! 100H! 115!
D! 114! 101! 116!
Y! 115! 102! 117!
Light!Chain!
Residue! Sequence! Kabat! IMGT!
CDR:L1!
T! 23! 24! 24!
G! 24! 25! 25!
S! 25! 26! 26!
S! 26! 27! 27!
S! 27! 27A! 28!
N! 28! 27B! 29!
I! 29! 27C! 30!
G! 30! 28! 31!
A! 31! 29! 35!
G! 32! 30! 36!
F! 33! 31! 37!
D! 34! 32! 38!
V! 35! 33! 39!
H! 36! 34! 40!
CDR:L2!
D! 52! 50! 56!
N! 53! 51! 57!
N! 54! 52! 65!
N! 55! 53! 66!
R! 56! 54! 67!
P! 57! 55! 68!
S! 58! 56! 69!
CDR:L3!
Q! 91! 89! 105!
S! 92! 90! 106!
Y! 93! 91! 107!
D! 94! 92! 108!
T! 95! 93! 109!
S! 96! 94! 110!
L! 97! 95! 112!
S! 98! 95A! 113!
G! 99! 95B! 114!
P! 100! 95C! 115!
V! 101! 96! 116!
V! 102! 97! 117!
F! 103! 98! 118!
G! 104! 99! 119!
G! 105! 100! 120!
G! 106! 101! 121!
T! 107! 102! 122!
K! 108! 103! 123!
L! 109! 104! 124!
T! 110! 105! 125!
V! 111! 106! 126!
L! 112! 107! 127!
Supplemental Figure 1. Fc-mediated innate immune effector functions. Related to Figure 4. 
MR78, MR82 and MR191 were evaluated for induction of antibody-dependent phagocytosis of 
RAVV GP-coated beads by human monocytes (A), neutrophils (B), or monocyte-derived 
dendritic cells (C). Activation of monocyte-derived dendritic cells following phagocytosis was 
determined by upregulation of HLA-DR, CD80, and CD86. Antibody-dependent activation of 
human NK cells was determined by degranulation as marked by expression of CD107a, and 
production of IFNγ and MIP-1β. Dashed line represents the levels of the no-antibody control. 
MR191, which demonstrated complete protection of both nonhuman primates and guinea pigs 
(Mire et al., 2017), is colored green. MR78, which demonstrated partial protection of guinea 
pigs, is colored yellow. MR82, which failed to protect guinea pigs, is colored orange. Error bars 
indicate standard deviations. 
Supplemental Figure 2. Disordered glycan cap. Related to Figure 2. 
 A schematic of EBOV GP is shown at top and MARV GP below, with arrows indicating the 
respective furin cleavage sites. The mucin-like domain (MLD) is disordered in both EBOV and 
MARV. The “cap” in MARV GP is a region containing residues that are equivalent in primary 
sequence location to the glycan cap in EBOV GP, but the residues in those positions bear little 
homology to those in EBOV. Below, predicted disorder of residues in the glycan cap of EBOV 
(blue) or equivalent residues in MARV (green) calculated using PrDOS software (Ishida and 
Kinoshita, 2007) is shown. Residues shown above the red line are predicted to be disordered. 
Graph shows greater predicted disorder within the MARV “cap” region. 
Supplemental Figure 3. Supplemental mutagenesis of MR191 and RAVV GP. Related to 
Figure 3. 
 
MR191 IgG1 antibodies were mutated in their CDR H2 or L3 and tested by ELISA for binding 
to RAVV GP. Antibodies mutated in these regions did not demonstrate significant differences in 










Supplemental Figure 4. Rosetta comparative model. Related to Figure 1.  
 (A) Rosetta modeling of binding interaction between MR191 (orange) and RAVV GP (blue and 
gold). (B) The Fv region of MR191 was modeled from experimental crystallographic data 
(green) and Rosetta comparative modeling (orange). Several differences can be seen, most 












Supplemental Figure 5. RAVV and EBOV “wing” region comparison. Related to Figure 2.  
Comparison of RAVV GP and EBOV GP in the wing anchor region. The RAVV GP wing 
anchor (orange) binds between GP1 (blue) and GP2 (gold). In contrast, in EBOV, this space is 
occupied by the N terminus of GP1 (red). Despite different sequences of the RAVV GP2 wing 
and EBOV GP1 N terminus, both form antiparallel beta strands in this location.  
